Literature DB >> 12008957

Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome.

Lidija Covic1, Christopher Singh, Hedy Smith, Athan Kuliopulos.   

Abstract

Individuals with Hermansky-Pudlak Syndrome (HPS) lack platelet dense granules and have no ADP-autocrine response. Despite these platelet deficiencies, HPS patients exhibit a surprisingly mild bleeding phenotype. We hypothesize that activation of the PAR4 thrombin receptor compensates for the lack of an ADP-autocrine response by the P2Y12 ADP receptor in individuals with HPS. Here, we determine that PAR4 activation by thrombin occurs well after ADP release from dense granules in normal individuals. However, the signal from PAR4 stabilizes platelet-platelet aggregate formation in the absence of P2Y12 activation by ADP. Thus, the strong signal emanating from PAR4 during platelet aggregation would provide an explanation for the mild bleeding diathesis of HPS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12008957

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

1.  Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4.

Authors:  María de la Fuente; Daniel N Noble; Sheetal Verma; Marvin T Nieman
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

Review 2.  G-protein-coupled receptors signaling pathways in new antiplatelet drug development.

Authors:  Paul A Gurbel; Athan Kuliopulos; Udaya S Tantry
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-29       Impact factor: 8.311

3.  Differential involvement of thrombin receptors in Ca2+ release from two different intracellular stores in human platelets.

Authors:  Isaac Jardin; Nidhal Ben Amor; Ahgleb Bartegi; José A Pariente; Ginés M Salido; Juan A Rosado
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

Review 4.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

5.  Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.

Authors:  Carey Kimmelstiel; Ryan Stevenson; Nga Nguyen; Layla Van Doren; Ping Zhang; James Perkins; Navin K Kapur; Andrew Weintraub; Vilma Castaneda; Athan Kuliopulos; Lidija Covic
Journal:  Thromb Res       Date:  2019-02-13       Impact factor: 3.944

Review 6.  Current and future antiplatelet therapies: emphasis on preserving haemostasis.

Authors:  James D McFadyen; Mathieu Schaff; Karlheinz Peter
Journal:  Nat Rev Cardiol       Date:  2018-01-03       Impact factor: 32.419

7.  Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.

Authors:  Anika Agarwal; Sarah L Tressel; Rajani Kaimal; Marianthi Balla; Francis H Lam; Lidija Covic; Athan Kuliopulos
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

8.  Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.

Authors:  Ping Zhang; András Gruber; Shogo Kasuda; Carey Kimmelstiel; Katie O'Callaghan; Daniel H Cox; Andrew Bohm; James D Baleja; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2012-06-15       Impact factor: 29.690

9.  Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.

Authors:  Amal Arachiche; Michele M Mumaw; María de la Fuente; Marvin T Nieman
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

Review 10.  Platelet thrombin receptor antagonism and atherothrombosis.

Authors:  Dominick J Angiolillo; Davide Capodanno; Shinya Goto
Journal:  Eur Heart J       Date:  2009-11-30       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.